Kairos Pharma (NYSEAMERICAN:KAPA) Trading Down 4.1% – Here’s Why

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) fell 4.1% during mid-day trading on Wednesday . The stock traded as low as $0.3666 and last traded at $0.3681. Approximately 72,087 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 123,271 shares. The stock had previously closed at $0.3837.

Kairos Pharma Price Performance

The stock has a 50 day simple moving average of $0.49 and a 200 day simple moving average of $0.61. The company has a market cap of $7.92 million, a price-to-earnings ratio of -1.23 and a beta of 1.50.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter. As a group, equities research analysts expect that Kairos Pharma, Ltd. will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KAPA. XTX Topco Ltd grew its holdings in Kairos Pharma by 290.8% during the 4th quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock valued at $34,000 after purchasing an additional 36,086 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Kairos Pharma in the 3rd quarter worth $27,000. Finally, Two Sigma Investments LP purchased a new position in Kairos Pharma in the 3rd quarter valued at about $54,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical?stage biopharmaceutical company focused on developing small?molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full?length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.